CytoSorbents Q4 Revenue Reaches $9.23M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy CTSO?
Reports Q4 revenue $9.23M vs. $9.15M last year. "2025 was a transitional year for our business as we made good progress in four key objectives," stated Dr. Phillip Chan, CEO of CytoSorbents. "We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth. Additionally, we continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR and look forward to providing further updates in the future."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTSO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTSO
Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.696
Low
0.75
Averages
0.75
High
0.75
Current: 0.696
Low
0.75
Averages
0.75
High
0.75
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytosorbents Q4 2025 Earnings Call Insights
- Sales Growth: Cytosorbents reported full-year 2025 sales revenue of $37.1 million, a 4% increase year-over-year, with direct sales outside Germany rising by 13%, indicating successful international market expansion.
- Challenges in Germany: Despite a 10% decline in German sales to $11.8 million, management noted early signs of improvement in Q1 2026, suggesting that restructuring efforts are beginning to yield positive results.
- FDA Progress and Product Launch: Although the FDA denied the initial DrugSorb-ATR submission, management confirmed no safety concerns and plans to focus on remaining issues for a new submission, while launching the PuriFi hemoperfusion pump to expand market access.
- Financial Performance and Outlook: Q4 2025 revenue was $9.2 million with a gross margin increase to 74%; despite an operating loss of $4.6 million, management remains optimistic about achieving cash flow breakeven in the second half of 2026.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
Cytosorbents Reports Q4 and Full Year 2025 Financial Results
- Revenue Growth: Cytosorbents reported total revenue of $37.1 million for the fiscal year 2025, marking a 4% increase compared to $35.6 million in 2024, indicating stability and potential growth opportunities in the market despite flat performance on a constant currency basis.
- Gross Margin Improvement: The gross margin for 2025 was 71%, up from 70% in 2024, reflecting positive progress in cost control and pricing strategies, which enhances the company's profitability.
- Net Loss Reduction: The net loss for 2025 decreased to $8.2 million, or $0.13 per share, compared to a net loss of $20.7 million, or $0.38 per share in 2024, demonstrating significant improvement in the company's financial health.
- Adjusted EBITDA Loss Decline: The adjusted EBITDA loss for 2025 was $10.5 million, an improvement from the $11.5 million loss in 2024, showcasing the company's ongoing efforts in operational efficiency and cost management.
See More
Cytosorbents to Announce Q4 Earnings on March 25
- Earnings Announcement Schedule: Cytosorbents is set to release its Q4 2023 earnings report on March 25 after market close, with stakeholders keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a significant 66.7% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Forecast: Revenue is projected at $9.21 million, representing a modest 0.7% year-over-year increase, suggesting some market demand despite sluggish growth, which could inform future strategic adjustments.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting volatility in achieving financial targets, necessitating cautious evaluation of its financial stability.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Treatment
- Launch of HotSwap™: CytoSorbents introduces HotSwap™, designed to expedite the exchange of CytoSorb adsorbers for critically ill patients, enhancing treatment efficiency and reducing nursing workload, thereby improving patient outcomes and survival rates.
- Renewal of Strategic Partnership: The renewal of the exclusive distribution agreement with Aferetica Srl strengthens market position in Italy, with over a decade of collaboration facilitating the widespread adoption of CytoSorb in critical care and cardiac surgery.
- Supportive Clinical Data: At ISICEM 2026, CytoSorbents presented new clinical data showing significant improvements in vasopressor requirements, oxygenation, and fluid balance for ICU patients treated with CytoSorb, with an ICU mortality rate of 32.7%, lower than predicted.
- Enhanced Scientific Leadership: The symposium hosted by CytoSorbents at ISICEM emphasized the importance of personalized treatment, showcasing its leadership in blood purification and further solidifying CytoSorb's role as a frontline therapy across critical illnesses.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Therapy
- Launch of HotSwap™: CytoSorbents introduced HotSwap™ at the ISICEM in Brussels, designed for rapid, seamless exchange of CytoSorb adsorbers during critical patient treatment, significantly enhancing treatment efficiency and helping clinicians better manage conditions to reduce organ failure risks.
- Renewal of Strategic Partnership: The company renewed its exclusive distribution agreement with Aferetica Srl, a collaboration exceeding a decade that has successfully promoted CytoSorb's clinical adoption in Italy, with plans to continue innovating in blood purification and organ transplantation to improve patient care.
- Clinical Data Presentation: At ISICEM 2026, CytoSorbents showcased multiple clinical data sets, including the COSMOS registry with 306 patients, reinforcing the application value of CytoSorb across various critical illnesses and boosting clinician confidence in the therapy.
- Optimistic Market Outlook: With the launch of HotSwap™ and the deepening of strategic partnerships, CytoSorbents is poised to strengthen its market position in critical care treatment, which is expected to drive future revenue growth and increase market share.
See More
Cytosorbents Q4 2025 Earnings Call Insights
- Sales Growth: Cytosorbents reported full-year 2025 sales revenue of $37.1 million, a 4% increase year-over-year, with direct sales outside Germany rising by 13%, indicating successful international market expansion.
- Challenges in Germany: Despite a 10% decline in German sales to $11.8 million, management noted early signs of improvement in Q1 2026, suggesting that restructuring efforts are beginning to yield positive results.
- FDA Progress and Product Launch: Although the FDA denied the initial DrugSorb-ATR submission, management confirmed no safety concerns and plans to focus on remaining issues for a new submission, while launching the PuriFi hemoperfusion pump to expand market access.
- Financial Performance and Outlook: Q4 2025 revenue was $9.2 million with a gross margin increase to 74%; despite an operating loss of $4.6 million, management remains optimistic about achieving cash flow breakeven in the second half of 2026.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
Cytosorbents Reports Q4 and Full Year 2025 Financial Results
- Revenue Growth: Cytosorbents reported total revenue of $37.1 million for the fiscal year 2025, marking a 4% increase compared to $35.6 million in 2024, indicating stability and potential growth opportunities in the market despite flat performance on a constant currency basis.
- Gross Margin Improvement: The gross margin for 2025 was 71%, up from 70% in 2024, reflecting positive progress in cost control and pricing strategies, which enhances the company's profitability.
- Net Loss Reduction: The net loss for 2025 decreased to $8.2 million, or $0.13 per share, compared to a net loss of $20.7 million, or $0.38 per share in 2024, demonstrating significant improvement in the company's financial health.
- Adjusted EBITDA Loss Decline: The adjusted EBITDA loss for 2025 was $10.5 million, an improvement from the $11.5 million loss in 2024, showcasing the company's ongoing efforts in operational efficiency and cost management.
See More
Cytosorbents to Announce Q4 Earnings on March 25
- Earnings Announcement Schedule: Cytosorbents is set to release its Q4 2023 earnings report on March 25 after market close, with stakeholders keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a significant 66.7% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Forecast: Revenue is projected at $9.21 million, representing a modest 0.7% year-over-year increase, suggesting some market demand despite sluggish growth, which could inform future strategic adjustments.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting volatility in achieving financial targets, necessitating cautious evaluation of its financial stability.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Treatment
- Launch of HotSwap™: CytoSorbents introduces HotSwap™, designed to expedite the exchange of CytoSorb adsorbers for critically ill patients, enhancing treatment efficiency and reducing nursing workload, thereby improving patient outcomes and survival rates.
- Renewal of Strategic Partnership: The renewal of the exclusive distribution agreement with Aferetica Srl strengthens market position in Italy, with over a decade of collaboration facilitating the widespread adoption of CytoSorb in critical care and cardiac surgery.
- Supportive Clinical Data: At ISICEM 2026, CytoSorbents presented new clinical data showing significant improvements in vasopressor requirements, oxygenation, and fluid balance for ICU patients treated with CytoSorb, with an ICU mortality rate of 32.7%, lower than predicted.
- Enhanced Scientific Leadership: The symposium hosted by CytoSorbents at ISICEM emphasized the importance of personalized treatment, showcasing its leadership in blood purification and further solidifying CytoSorb's role as a frontline therapy across critical illnesses.
See More
CytoSorbents Launches HotSwap™ to Optimize Critical Care Therapy
- Launch of HotSwap™: CytoSorbents introduced HotSwap™ at the ISICEM in Brussels, designed for rapid, seamless exchange of CytoSorb adsorbers during critical patient treatment, significantly enhancing treatment efficiency and helping clinicians better manage conditions to reduce organ failure risks.
- Renewal of Strategic Partnership: The company renewed its exclusive distribution agreement with Aferetica Srl, a collaboration exceeding a decade that has successfully promoted CytoSorb's clinical adoption in Italy, with plans to continue innovating in blood purification and organ transplantation to improve patient care.
- Clinical Data Presentation: At ISICEM 2026, CytoSorbents showcased multiple clinical data sets, including the COSMOS registry with 306 patients, reinforcing the application value of CytoSorb across various critical illnesses and boosting clinician confidence in the therapy.
- Optimistic Market Outlook: With the launch of HotSwap™ and the deepening of strategic partnerships, CytoSorbents is poised to strengthen its market position in critical care treatment, which is expected to drive future revenue growth and increase market share.
See More
